EMD Chemicals, MitoSciences to Co-develop Assays | GenomeWeb

NEW YORK (GenomeWeb News) – Merck KGaA subsidiary EMD Chemicals yesterday said that it will work with MitoSciences to develop assays for drug toxicity and mitochondrial bioactivity.

The firms intend to co-develop multiplex immunoassay products for EMD's WideScreen BeadPlex assay platform for detecting and profiling mitochondrial toxicity and activity. The WideScreen assays run on a Luminex xMAP system.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.